Phenolphthalein

Summary

Phenolphthalein (CHEMBL63857) is an approved small molecule (ATC A06AB04); indicated across 1 condition including constipation disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A06AB04
• Indications: 1 condition
• Chemistry: 318.3 Da · C20H14O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL63857
Name	Phenolphthalein
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4764
ATC	A06AB04
Molecular formula	C20H14O4
Molecular weight	318.3
InChIKey	KJFMBFZCATUALV-UHFFFAOYSA-N

SMILES: C1=CC=C2C(=C1)C(=O)OC2(C3=CC=C(C=C3)O)C4=CC=C(C=C4)O

IUPAC name: 3,3-bis(4-hydroxyphenyl)-2-benzofuran-1-one

Also known as: Alophen, Fenolftaleina, Phenolphtaleine, Phenolphthalein, SID17389766, SID26747045, SID26751565, SID855935, phenolphthalein, SID104171370, SID26747046, SID50100917

Patent coverage: 26,461 distinct patent families (57,577 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 57,118 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 19 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, G-protein coupled receptor 55, Microtubule-associated protein tau, Survival motor neuron protein, Prelamin-A/C, Thymidylate synthase, Thymidylate synthase, Thyrotropin receptor, Estrogen receptor, Menin/Histone-lysine N-methyltransferase MLL.

Bioactivity

ChEMBL activities: 14 potent at pChembl ≥ 5 of 27 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	7.6	Potency	25.1	nM	CHEMBL_ACT_3647421
SMN1	6.45	Potency	354.8	nM	CHEMBL_ACT_3879134
TYMS	5.92	Ki	1200	nM	CHEMBL_ACT_6307481
Q834R3	5.85	Ki	1400	nM	CHEMBL_ACT_6307525
P15917	5.6	Potency	2512	nM	CHEMBL_ACT_4634876
ESR1	5.43	IC50	3700	nM	CHEMBL_ACT_26732355
CYP3A4	5.4	Potency	3981	nM	CHEMBL_ACT_4981868
CYP3A4	5.4	Potency	3981	nM	CHEMBL_ACT_5050930
P00469	5.33	Ki	4700	nM	CHEMBL_ACT_6307528
P0A884	5.33	Ki	4700	nM	CHEMBL_ACT_684649
CYP3A4	5.2	Potency	6310	nM	CHEMBL_ACT_5002225
CYP3A4	5.2	Potency	6310	nM	CHEMBL_ACT_5070839
GPR55	5.18	IC50	6667	nM	CHEMBL_ACT_5665324
P00469	5.16	Ki	7000	nM	CHEMBL_ACT_13833454

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
constipation disorder	4	MONDO:0002203	HP:0002019

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).